{"id":97975,"date":"2009-12-22T13:57:41","date_gmt":"2009-12-22T18:57:41","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2009\/12\/22\/rd-spending-numbers-for-pfizer-jj-merck-lilly-and-bristol\/"},"modified":"2009-12-22T13:57:41","modified_gmt":"2009-12-22T18:57:41","slug":"rd-spending-numbers-for-pfizer-jj-merck-lilly-and-bristol","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/97975","title":{"rendered":"R&D Spending: Numbers for Pfizer, J&J, Merck, Lilly and Bristol"},"content":{"rendered":"

\"PharmaceuticalU.S. investment in R&D fell slightly this year, and is expected to start growing again next year, according to a new report out from the Battelle Memorial Institute<\/a>, a nonprofit group that looks at that sort of thing.<\/p>\n

A story<\/a> in this morning’s WSJ has more on the issue; Health Blog readers may be particularly interested in some numbers from the report on R&D spending at big U.S. drug companies.<\/p>\n

Of course, company-by-company figures like these don’t tell the whole story, in part because of the effects of consolidation. For example, Pfizer’s R&D spending may climb next year because of the Wyeth acquisition, but continuing cuts<\/a> could mean the company’s R&D spending is lower than this year’s combined R&D spending for Pfizer and Wyeth.<\/p>\n

Nevertheless, a numbers dump can still be interesting. Here it is:<\/p>\n

R&D Spending, in millions of dollars<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Company<\/strong><\/td>\nQ1-Q3, ‘08<\/strong><\/td>\nQ1-Q3, ‘09<\/strong><\/td>\nChange<\/strong><\/td>\n<\/tr>\n
Pfizer<\/td>\n$5,642<\/td>\n$5,032<\/td>\n-10.8%<\/td>\n<\/tr>\n
J&J<\/td>\n$5,469<\/td>\n$4,773<\/td>\n-12.7%<\/td>\n<\/tr>\n
Merck<\/td>\n$3,419<\/td>\n$3,874<\/td>\n13.3%<\/td>\n<\/tr>\n
Eli Lilly<\/td>\n$2,782<\/td>\n$3,110<\/td>\n11.8%<\/td>\n<\/tr>\n
Bristol-Myers Squibb<\/td>\n$2,442<\/td>\n$2,590<\/td>\n6.1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Photo: Associated Press<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

U.S. investment in R&D fell slightly this year, and is expected to start growing again next year, according to a new report out from the Battelle Memorial Institute, a nonprofit group that looks at that sort of thing. A story in this morning’s WSJ has more on the issue; Health Blog readers may be particularly […]<\/p>\n","protected":false},"author":650,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-97975","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/97975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/650"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=97975"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/97975\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=97975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=97975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=97975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}